Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 217: Japanese Investment in North Carolina’s Life Sciences Industry with David Robinson of Maynard Nexsen
Legal Alert | Japan is Primed for Increased Foreign Direct Investment
Patent Grace Period Considerations in Australia, Japan, South East Asia and the U.S.
Greater Speed and Efficiency: Steps IP Offices Around the World Are Taking to Streamline the Patent Process
Nota Bene Episode 109: Asia Q1 Check In: China’s Emergence as the Number One World Economy and New Hegemonic Role in Asia with Paul Kim
Nota Bene Episode 69: Asia Check In: The Coronavirus’s Impact on Business, the Trilateral Summit, and Japan’s Criminal Justice System with Paul Kim
Dr. Frederick Ch’en discusses generic drugs and the changing pharmaceutical landscape in Asia
Spencer Klein Talks M&A with Mergers & Acquisitions Magazine
The Trump administration's imposition of tariffs on steel, aluminum, lumber, and other construction materials, in combination with increased tariffs on raw materials and finished goods from China, Japan, the EU, and...more
Welcome to Industrials Regulatory News and Trends. In this regular bulletin, DLA Piper lawyers provide concise updates on key developments in the industrials sector to help you navigate the ever-changing business, legal, and...more
On March 26, President Trump issued Proclamation 10908, “Adjusting Imports of Automobiles and Automobile Parts Into the United States” (Proclamation), imposing a 25% additional tariff on imports of passenger vehicles, light...more
President Trump issued a Proclamation that expands the 25% tariffs on steel and steel derivatives, first imposed in 2018 under Section 232 of the Trade Expansion Act of 1962. Aluminum and aluminum derivatives will also now...more
The global transition from internal combustion engines (ICE) to battery electric vehicles (BEV) will be transformative and disruptive, if not existential, for many segments of the automotive industry. All direct and indirect...more
Amgen will pay $13.4 billion in cash to buy psoriasis treatment Otezla, a deal that will “pave the way for Bristol-Myers Squibb to complete its acquisition of Celgene” by addressing “regulatory concerns over their union”....more